Table 2.

Success states by pillar identified by Global Advisory Committee members in phase II

Drug development	Clinical care	Access to care
Improved trial design across age groups	Biomarkers to support timely and accurate diagnosis	Access to high quality, specialised care regardless of location
Improved outcome measures to be uniformly implemented across sponsors	Improved support programmes to encourage treatment adherence among patients	Improved access to care for individuals of lower socioeconomic status
Improved biomarkers to better define heterogeneity and predict response to investigational therapies	Biomarkers to predict patients’ responses to therapies to support design of treatment regimens	Improved global access to advanced diagnostics and therapies